8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
May 22, 2026·SEC
Material company update
May 14, 2026·SEC
Tempest Therapeutics, Inc.(TPST)Earnings, Financials & Key Ratios
TPST•NASDAQ
Price updated Jun 19, 2026
AboutTempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.Show more
- Revenue$0
- EBITDA-$26M+36.8%
- Net Income-$26M+37.2%
- EPS (Diluted)-6.33-322.0%
- ROE-203.63%-11.7%
TPST Key Insights
Tempest Therapeutics, Inc. (TPST) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 85.1% through buybacks
- ✓Trading at only 0.8x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 4 (bottom 4%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TPST posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TPST Price & Volume
Tempest Therapeutics, Inc. (TPST) stock price & volume — 10-year historical chart
Loading chart...
TPST Growth Metrics
Tempest Therapeutics, Inc. (TPST) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM3.8%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-38.31%
Return on Capital
10 Years-73.84%
5 Years-94.47%
3 Years-107.67%
Last Year-130%
TPST Recent Earnings
Tempest Therapeutics, Inc. (TPST) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$2.53-803.6%
$0.28
Rev
—
—
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$0.62+0.0%
$0.62
Rev
—
—
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.79+75.8%
$3.27
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$2.07+35.9%
$3.23
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $2.53vs $0.28-803.6% | — |
| Q2 2026 | Mar 31, 2026 | $0.62vs $0.62+0.0% | — |
| Q4 2025 | Nov 5, 2025 | $0.79vs $3.27+75.8% | — |
| Q3 2025 | Aug 11, 2025 | $2.07vs $3.23+35.9% | — |
Based on last 12 quarters of dataView full earnings history →
TPST Peer Comparison
Tempest Therapeutics, Inc. (TPST) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 AGIO | 2.03B | 34.16 | -4.80 | 48.03% | -6.4% | -34.11% | 0.05 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 | |
 CRIS | 81.52M | 0.42 | -0.73 | -13.43% | -299.66% | -138.81% | 0.30 |
Compare TPST vs Peers
Tempest Therapeutics, Inc. (TPST) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TPST Income Statement
Tempest Therapeutics, Inc. (TPST) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 295K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | -54.82% | -100% | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 28K | 32K | 0 | 815K | 0 | 0 | 0 | 389K | 0 | 22.25M |
COGS % of Revenue | 9.49% | - | - | - | - | - | - | - | - | - |
Gross Profit | 267K▲ 0% | -32K▼ 112.0% | -1.05M▼ 3187.5% | -815K▲ 22.5% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | -389K▲ 0% | 0▲ 100.0% | -22.25M▲ 0% |
Gross Margin % | 90.51% | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | 105.62% | -111.98% | -3187.5% | 22.53% | 100% | - | - | - | 100% | - |
Operating Expenses | 20.45M | 23.08M | 44.35M | 18.48M | 26.99M | 34.64M | 29.16M | 41.64M | 26.57M | 21.11M |
OpEx % of Revenue | 6933.56% | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 5.93M | 8.66M | 16.5M | 4.09M | 9.82M | 12.11M | 11.66M | 13.55M | 13.97M | 16.09M |
SG&A % of Revenue | 2009.49% | - | - | - | - | - | - | - | - | - |
Research & Development | 14.53M | 14.43M | 27.84M | 14.39M | 17.17M | 22.53M | 17.5M | 28.48M | 12.61M | 5.09M |
R&D % of Revenue | 4924.07% | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -389K | 0 | -67K |
Operating Income | -20.48M▲ 0% | -23.12M▼ 12.9% | -45.4M▼ 96.4% | -19.3M▲ 57.5% | -26.99M▼ 39.8% | -34.64M▼ 28.4% | -29.16M▲ 15.8% | -42.03M▼ 44.1% | -26.57M▲ 36.8% | -43.36M▲ 0% |
Operating Margin % | -6943.05% | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | 74.72% | -12.86% | -96.4% | 57.49% | -39.84% | -28.36% | 15.83% | -44.14% | 36.77% | - |
EBITDA | -20.45M | -23.08M | -44.35M | -18.48M | -26.61M | -34M | -28.78M | -41.64M | -26.31M | -43.16M |
EBITDA Margin % | -6933.56% | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | 74.03% | -12.86% | -92.11% | 58.32% | -43.98% | -27.77% | 15.37% | -44.69% | 36.81% | 3.27% |
D&A (Non-Cash Add-back) | 28K | 32K | 1.05M | 815K | 374K | 638K | 381K | 389K | 266K | 198K |
EBIT | -84.3M | -27.04M | -44.57M | -19.21M | -27.02M | -34.09M | -28.04M | -40.53M | -26.05M | -43.08M |
Net Interest Income | 0 | 0 | 264K | 90K | -1.28M | -1.07M | -334K | 183K | 313K | 214K |
Interest Income | 0 | 0 | 264K | 90K | 1.28K | 549K | 1.11M | 1.5M | 520K | 283K |
Interest Expense | 0 | 134K | 0 | 0 | 1.28M | 1.62M | 1.45M | 1.32M | 207K | 69K |
Other Income/Expense | -64.1M | -4.06M | 831K | 90K | -1.32M | -1.07M | -334K | 183K | 313K | 261K |
Pretax Income | -84.59M▲ 0% | -27.18M▲ 67.9% | -44.57M▼ 64.0% | -19.21M▲ 56.9% | -28.3M▼ 47.3% | -35.71M▼ 26.2% | -29.49M▲ 17.4% | -41.84M▼ 41.9% | -26.26M▲ 37.2% | -43.1M▲ 0% |
Pretax Margin % | -28673.22% | - | - | - | - | - | - | - | - | - |
Income Tax | 67K | -169K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -0.08% | 0.62% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -84.58M▲ 0% | -27.19M▲ 67.8% | -44.57M▼ 63.9% | -19.12M▲ 57.1% | -28.3M▼ 48.0% | -35.71M▼ 26.2% | -29.49M▲ 17.4% | -41.84M▼ 41.9% | -26.26M▲ 37.2% | -43.1M▲ 0% |
Net Margin % | -28670.51% | - | - | - | - | - | - | - | - | - |
Net Income Growth % | -2.82% | 67.85% | -63.9% | 57.1% | -48.04% | -26.17% | 17.41% | -41.88% | 37.24% | 3.8% |
Net Income (Continuing) | -84.59M | -27.18M | -44.57M | -19.21M | -28.3M | -35.71M | -29.49M | -41.84M | -26.26M | -43.1M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 12.76M | 2.17M | 1.32M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -72406.33▲ 0% | -263.65▲ 99.6% | -48.77▲ 81.5% | -612.56▼ 1156.0% | -7.80▲ 98.7% | -3.18▲ 59.2% | -1.91▲ 39.9% | -1.50▲ 21.5% | -6.33▼ 322.0% | -3.94▲ 0% |
EPS Growth % | -12476.44% | 99.64% | 81.5% | -1156.02% | 98.73% | 59.23% | 39.94% | 21.47% | -322% | -38.31% |
EPS (Basic) | -72406.33 | -263.65 | -48.77 | -612.56 | -7.80 | -3.18 | -1.91 | -1.50 | -6.33 | - |
Diluted Shares Outstanding | 1.17K | 103.14K | 913.78K | 31.21K | 291.56K | 888.38K | 15.42M | 27.9M | 4.15M | 10.93M |
Basic Shares Outstanding | 1.17K | 103.14K | 913.78K | 31.21K | 291K | 888K | 15.42M | 27.9M | 4.15M | 10.93M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TPST Balance Sheet
Tempest Therapeutics, Inc. (TPST) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 19.74M | 83.42M | 71.13M | 19.82M | 68.96M | 32.95M | 40.36M | 31.47M | 8.27M | 2.45M |
Cash & Short-Term Investments | 67.2M | 77.72M | 63.51M | 18.82M | 51.83M | 31.23M | 39.23M | 30.27M | 7.71M | 1.8M |
Cash Only | 15.7M | 73.33M | 63.51M | 18.82M | 51.83M | 31.23M | 39.23M | 30.27M | 7.71M | 1.8M |
Short-Term Investments | 51.5M | 4.38M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 1.03M | 2.33M | 1.28M | 260K | 15M | 450K | 0 | 0 | 0 | 0 |
Days Sales Outstanding | 1.28K | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 1.58M | 3.37M | 6.34M | 59K | 553K | 263K | 96K | 535K | 562K | 641K |
Total Non-Current Assets | 74K | 652K | 3.84M | 3.04M | 4.28M | 13.14M | 11.24M | 10.01M | 8.66M | 8.3M |
Property, Plant & Equipment | 3.11M | 0 | 3.33M | 2.99M | 4.16M | 12.71M | 10.79M | 9.53M | 8.14M | 7.79M |
Fixed Asset Turnover | 0.09x | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 146K | 439K | 0 | 0 | 0 | 0 | 0 | 388K | 0 | 388K |
Other Non-Current Assets | -3.19M | 213K | 507K | 51K | 111K | 429K | 448K | 97K | 517K | 509K |
Total Assets | 19.81M▲ 0% | 84.07M▲ 324.4% | 74.97M▼ 10.8% | 22.86M▼ 69.5% | 73.24M▲ 220.3% | 46.09M▼ 37.1% | 51.6M▲ 12.0% | 41.49M▼ 19.6% | 16.93M▼ 59.2% | 10.75M▲ 0% |
Asset Turnover | 0.01x | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | -83.83% | 324.36% | -10.83% | -69.5% | 220.33% | -37.07% | 11.96% | -19.6% | -59.19% | -217.09% |
Total Current Liabilities | 4.09M | 9.82M | 12.52M | 3.22M | 20.03M | 7.28M | 9.41M | 14.22M | 3.31M | 3.31M |
Accounts Payable | 2.24M | 2M | 1.5M | 1.07M | 991K | 1.11M | 845K | 2.45M | 1.04M | 585K |
Days Payables Outstanding | 29.23K | 22.79K | - | 479.65 | - | - | - | 2.3K | - | 29.78 |
Short-Term Debt | 174K | 189K | 1.96M | 0 | 0 | 0 | 4.29M | 6.35M | 1.19M | 1.24M |
Deferred Revenue (Current) | 334K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2.29M | 7.63M | 7.02M | 774K | 912K | 1.25M | 1.79M | 0 | 1.08M | 1.49M |
Current Ratio | 4.82x | 8.50x | 5.68x | 6.15x | 3.44x | 4.53x | 4.29x | 2.21x | 2.50x | 0.74x |
Quick Ratio | 4.82x | 8.50x | 5.68x | 6.15x | 3.44x | 4.53x | 4.29x | 2.21x | 2.50x | 0.74x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 738K | 1.14M | 2.58M | 88.43M | 17.09M | 20.7M | 15.42M | 8.14M | 6.95M | 6.62M |
Long-Term Debt | 599K | 383K | 168K | 0 | 15.07M | 10.37M | 6.26M | 0 | 6.95M | 6.62M |
Capital Lease Obligations | 0 | 0 | 2.4M | 1.73M | 2.03M | 10.33M | 9.16M | 8.14M | 0 | 14.82M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 139K | 752K | 16K | 86.71M | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 4.83M | 10.95M | 15.1M | 91.66M | 37.12M | 27.98M | 24.84M | 22.36M | 10.26M | 9.93M |
Total Debt | 773K | 572K | 4.52M | 2.44M | 18.54M | 22.11M | 20.66M | 15.37M | 8.14M | 7.85M |
Net Debt | -16.85M | -72.76M | -58.99M | -16.38M | -33.29M | -9.12M | -18.57M | -14.9M | 434K | 6.05M |
Debt / Equity | 0.05x | 0.01x | 0.08x | - | 0.51x | 1.22x | 0.77x | 0.80x | 1.22x | 9.55x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.18x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.14x |
Interest Coverage | - | -201.81x | - | - | -21.08x | -21.07x | -19.35x | -30.80x | -125.87x | -624.28x |
Total Equity | 14.98M▲ 0% | 73.12M▲ 388.0% | 59.87M▼ 18.1% | -68.79M▼ 214.9% | 36.12M▲ 152.5% | 18.11M▼ 49.9% | 26.77M▲ 47.8% | 19.13M▼ 28.5% | 6.67M▼ 65.1% | 822K▲ 0% |
Equity Growth % | -86.15% | 388.03% | -18.12% | -214.9% | 152.5% | -49.85% | 47.8% | -28.55% | -65.14% | -244.61% |
Book Value per Share | 12827.91 | 708.99 | 65.52 | -2204.20 | 123.87 | 20.39 | 1.74 | 0.69 | 1.61 | 0.08 |
Total Shareholders' Equity | 2.23M | 70.95M | 58.55M | -68.79M | 36.12M | 18.11M | 26.77M | 19.13M | 6.67M | 822K |
Common Stock | 36K | 13K | 18K | 1K | 7K | 11K | 22K | 44K | 5K | 14K |
Retained Earnings | -136.89M | -164.09M | -208.65M | -71.76M | -100.06M | -135.77M | -165.26M | -207.11M | -233.37M | -270.07M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -19K | 148K | 165K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 12.76M | 2.17M | 1.32M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TPST Cash Flow Statement
Tempest Therapeutics, Inc. (TPST) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -20.34M | -23.65M | -41.22M | -19.02M | -25.96M | -31.07M | -27.36M | -33.03M | -26.82M | -26.38M |
Operating CF Margin % | -6894.92% | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | 67.05% | -16.26% | -74.32% | 53.87% | -36.49% | -19.71% | 11.96% | -20.73% | 18.79% | 50.64% |
Net Income | -84.58M | -27.19M | -44.57M | -19.21M | -28.3M | -35.71M | -29.49M | -41.84M | -26.26M | -43.1M |
Depreciation & Amortization | 1.65M | 32K | 1.05M | 339K | 374K | 638K | 381K | 389K | 266K | 258K |
Stock-Based Compensation | 6.89M | 1.43M | 0 | 453K | 1.1M | 1.56M | 2.55M | 5.3M | 3.12M | 1.96M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 66.05M | 0 | 4.35M | 470K | 1.48M | 1.57M | 1.88M | 1.51M | 1.19M | 21.1M |
Working Capital Changes | -1.84M | 1.04M | -2.05M | -1.07M | -613K | 868K | -2.68M | 1.61M | -5.13M | -6.6M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -1.45M | 320K | -469K | -574K | -209K | 1K | -263K | 1.6M | -1.41M | -1.6M |
Cash from Investing | 458K | 1.12M | 3.99M | -6K | -97K | -562K | -170K | -435K | 0 | 0 |
Capital Expenditures | -158K | -36K | -397K | -50K | -135K | -562K | -170K | -435K | 0 | 0 |
CapEx % of Revenue | 53.56% | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | -1.33M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -1.45M | 0 | 0 | 44K | 38K | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | -4.46M | 78.55M | 26.94M | 34.6M | 59.06M | 11.4M | 35.6M | 24.5M | 4.26M | 6.68M |
Debt Issued (Net) | -4.46M | 6.48M | -202K | 0 | 15M | -4.74M | 0 | -4.4M | -6.43M | -4.23M |
Equity Issued (Net) | 2K | 38.76M | 27.14M | 35M | 33.42M | 16.14M | 35.6M | 28.59M | 10.69M | 9.05M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 33.32M | 0 | -401K | 10.64M | 0 | 0 | 307K | 0 | 1.86M |
Net Change in Cash | -26.31M▲ 0% | 55.71M▲ 311.8% | -9.82M▼ 117.6% | 15.58M▲ 258.6% | 33.01M▲ 111.9% | -20.23M▼ 161.3% | 8.07M▲ 139.9% | -8.96M▼ 211.0% | -22.56M▼ 151.7% | -19.71M▲ 0% |
Free Cash Flow | -20.34M▲ 0% | -23.68M▼ 16.4% | -41.62M▼ 75.7% | -19.07M▲ 54.2% | -26.09M▼ 36.8% | -31.63M▼ 21.2% | -27.53M▲ 13.0% | -33.46M▼ 21.6% | -26.82M▲ 19.8% | -26.38M▲ 0% |
FCF Margin % | -6896.27% | - | - | - | - | - | - | - | - | - |
FCF Growth % | 68.37% | -16.41% | -75.73% | 54.19% | -36.84% | -21.24% | 12.98% | -21.56% | 19.85% | 22.73% |
FCF per Share | -17417.81 | -229.63 | -45.55 | -610.93 | -89.49 | -35.61 | -1.79 | -1.20 | -6.46 | -2.41 |
FCF Conversion (FCF/Net Income) | 0.24x | 0.87x | 0.92x | 0.99x | 0.92x | 0.87x | 0.93x | 0.79x | 1.02x | 0.61x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 1.54M | 1.25M | 1.18M | 192K | 44K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 18K | 191K | 54K | 43K | 43K |
TPST Key Ratios
Tempest Therapeutics, Inc. (TPST) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -137.3% | -61.73% | -67.02% | - | -78.36% | -131.7% | -131.42% | -182.35% | -203.63% | -729.89% |
Return on Invested Capital (ROIC) | -47.75% | -8335.1% | -5474.16% | - | - | -439.59% | -254.36% | -507.48% | -351.99% | -512.6% |
Gross Margin | 90.51% | - | - | - | - | - | - | - | - | - |
Net Margin | -28670.51% | - | - | - | - | - | - | - | - | - |
Debt / Equity | 0.05x | 0.01x | 0.08x | - | 0.51x | 1.22x | 0.77x | 0.80x | 1.22x | 9.55x |
Interest Coverage | - | -201.81x | - | - | -21.08x | -21.07x | -19.35x | -30.80x | -125.87x | -624.28x |
FCF Conversion | 0.24x | 0.87x | 0.92x | 0.99x | 0.92x | 0.87x | 0.93x | 0.79x | 1.02x | 0.61x |
Revenue Growth | -54.82% | -100% | - | - | - | - | - | - | - | - |
Related:TPST Dividend History·TPST Revenue History·TPST Price History·TPST P/E History·TPST Financial Ratios·TPST Institutional Holders
TPST SEC Filings & Documents
Tempest Therapeutics, Inc. (TPST) SEC filings — annual & quarterly reports (10-K, 10-Q)
TPST Frequently Asked Questions
Tempest Therapeutics, Inc. (TPST) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Tempest Therapeutics, Inc. (TPST) grew revenue by 0.0% over the past year. Growth has been modest.
Tempest Therapeutics, Inc. (TPST) reported a net loss of $43.1M for fiscal year 2025.
Dividend & Returns
Tempest Therapeutics, Inc. (TPST) has a return on equity (ROE) of -203.6%. Negative ROE indicates the company is unprofitable.
Tempest Therapeutics, Inc. (TPST) had negative free cash flow of $26.4M in fiscal year 2025, likely due to heavy capital investments.